# Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

> **NCT05053334** · PHASE1 · COMPLETED · sponsor: **Syneos Health** · enrollment: 165 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Omalizumab Prefilled Syringe

## Key facts

- **NCT ID:** NCT05053334
- **Lead sponsor:** Syneos Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-16
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05053334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05053334, "Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05053334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*